Anlotinib Recruiting Phase 2 Trials for Neoplasms, Lung / Carcinoma NOS / Non-Small Cell Lung Carcinoma (NSCLC) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03765775Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative